Studies from Memorial Sloan-Kettering Cancer Center Update Current Data on Pluripotent Stem Cells (Development of Induced Pluripotent Stem Cell-Derived T Cells Exhibiting Phenotypic and Functional Attributes of Primary CAR T Cells).

A recent study from Memorial Sloan-Kettering Cancer Center explores the development of induced pluripotent stem cell-derived T cells that exhibit similar characteristics to primary CAR T cells. The research highlights the potential of using iPSC-derived T cells as an off-the-shelf approach to cell therapy, addressing challenges in generating uniform drug products for patients. The study emphasizes the functional, phenotypic, and transcriptomic similarities between CD8ab+ iT cells and primary T cells, showcasing promising outcomes for cancer treatment. This research offers valuable insights into the potential of iPSC technology in advancing cell therapy options. [Extracted from the article]